As part of a larger team of consultants, I supported an established pharmaceutical company entering the Canadian market.

• Health-Economic Models: As Senior Health Economist, I developed a Cost Minimisation analysis and a Budget Impact model that were submitted to the Canadian and Québécois authorities.
• ITC feasibility assessment: I drafted a Statistical Analysis Plan (SAP) and conducted a feasibility study for a large ITC that included seven different products.

As part of a larger team of consultants, I assisted an established pharmaceutical company in reviewing the Value Story for a new product indicated for a rare form of autoimmune nephropathy.

As part of a larger team of consultants, I supported an established pharmaceutical company in reviewing the Global Value Dossier and the Value Story of a drug indicated for a rare vasculitis.

• Global Value Dossier: I reviewed and optimized the existing Global Value Dossier. This involved critically assessing the data, refining key messages, and ensuring consistency across the materials.
• Global Value Story: I refined the existing value propositions to clearly communicate the unmet need associated with the disease, as well as the product’s clinical and economic benefits.
• Cross-functional workshop: I led a cross-functional workshop with stakeholders from market access, marketing, medical, commercial, and senior management to align on key messaging and value strategies.

As part of a larger team of consultants, I supported a biotech company developing an FcRn inhibitor for two chronic neuromuscular diseases.

• Health-Economic Models: I developed two cost-effectiveness models comparing the new drug to existing therapies (rituximab, intravenous immunoglobulin, corticosteroids).
• Country adaptation: I helped adapt the models for pricing and reimbursement in France and the UK.
• Indirect treatment comparison: I conducted multiple Matching-Adjusted Indirect Treatment Comparisons to generate comparative evidence of the new intervention vs. existing treatment options.

As part of a larger team of consultants, I supported a biotech company in developing a KIT-mutant kinase inhibitor for a rare myeloid neoplasm, which has orphan drug designation in the EU.

• Health-Economic Models: I supported the development of a core cost-effectiveness model comparing the new product to existing treatments.
• Country adaptation: I helped adapt the model for reimbursement processes in France, Netherlands, the UK, and Italy (successful reimbursement).
• Analytics: I conducted longitudinal and survival analyses on patient-level data from the pivotal clinical trial.

As an independent consultant, I supported a biotech company developing a new monoclonal antibody for a non-solid tumor. The product was in a Phase IIb clinical trial and had orphan drug designation in the US and EU.

• Burden of Illness: I estimated the burden of illness associated with the target disease in the US, UK, and Germany.
• Cost-Effectiveness & Budget-Impact Models: I developed a cost-effectiveness model to compare the new product’s cost-effectiveness to existing treatment options (chemotherapy, CAR-T, HSCT). Additionally, I estimated the product’s budget impact in the UK.